Biotech Values

[mcbio]

DNLI -

sounds like a big gamble at this point.

I do love the novelty of the targets they are pursuing and management has good pedigree but agree with the valuation comments. As I said before, my gut is to at least wait until they have some early safety data in man to ensure there won't be tox concerns with the LRRK2 and RIPK1 drugs (given some of the concerns noted in pre-clinical work). Hopefully valuation will have come down some at that point as well. If those two things occur, then I might still be willing to take some type of gamble on there being at least some sort of efficacy signal in the clinic at some point from one of those two drugs (it's still a big gamble to be sure).